

# India Biosimilars Market latest trends, forecast and market analysis

*Market Research Report on India  
Biosimilars Market*

RAIPUR, CHHATTISGARH, INDIA,  
November 6, 2017 /EINPresswire.com/  
--

Report Sellers has added a new market research report "[Biosimilars Market in India 2017](#)" to its offerings. The report is an in-depth market study providing accurate market insights including the latest trends, forecast, competitive insights, etc.

The increasing incidence of diseases such as CVD and CHD, cancer and diabetes has led to an increase in the demand for these products and has resulted in the growth of this industry in India. Biosimilars are typically

marketed at prices that are 25% to 40% below the prices of original branded products. This has been the primary appeal to customers. Moreover, the rise in the number and quality of tertiary care centers is resulting in the greater usage of these products. Rising drug costs, limited healthcare budgets across the world and patent expiries of biotechnology drugs have created a huge opportunity for biosimilar manufacturers. There aren't too many players in the market and the industry is dominated by a small number of sellers leaving a room for the new entrants in the market.

However, required capital investment and operating costs for manufacturing is much higher for biosimilars than for generic drugs. The process to develop a generic version of biosimilar is also complex than developing a generic copy of a chemical-based compound. Extensive funding is required due to emerging rigorous regulatory requirements which act as a challenge for the players in the industry. Lack of widespread awareness towards the biosimilar products is also

The logo for REPORT SELLERS, with "REPORT" in blue and "SELLERS" in yellow.

India Biosimilars Market Research Report

acting as a drawback for the industry as people tend to avoid using biosimilar products. The stringent regulatory framework of the healthcare industry which requires biosimilars to undergo several regulatory measures is cumbersome for companies looking to constantly innovate and launch new products in the market. Although there are challenges in the industry, the market for biosimilars is expected to grow with more players entering the market and development of new biosimilar products for the treatment of chronic diseases.

Browse through the complete description and in-depth TOC on “India Biosimilars Market”  
<https://www.reportsellers.com/market-research-report/Biosimilars-Market-in-India-2017>

## Companies Mentioned

### Public Companies

1. Biocon Limited
2. Dr. Reddy's Laboratories Limited
3. Lupin Limited
4. Cipla Limited
5. Zenotech Laboratories Limited
6. Wockhardt Limited

### Private Companies

1. Intas Pharmaceuticals Limited
2. Bharat Biotech Limited
3. Reliance Life Sciences Private Limited
4. Shantha Biotechnics Private Limited

Request Sample here: <https://www.reportsellers.com/market-research-report/Biosimilars-Market-in-India-2017>

We have a large number of reports in other Pharmaceuticals Industry which can be accessed in the following link:

<https://www.reportsellers.com/sub-category/Pharmaceuticals-market-research-report>

## [About Report Sellers](#)

Report Sellers is a premium [market research service provider](#) offering market reports in varied sectors. We have a team of experienced analysts and publishers who continuously track the latest trends in different industries.

Report Sellers is a brand of global repute and offers the best suited research services to its clients globally in the most satisfying manner. We have a strong network of industry experts who have successfully delivered complex research assignments in niche and top markets.

For any research requirement, drop an enquiry at <https://www.reportsellers.com/contact-us> or send us email at [sales@reportsellers.com](mailto:sales@reportsellers.com)

Aditya Joshi  
Report Sellers  
+1-214-396-2385  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/413966707>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.